Login to get immediate access to this content.
LoginSpeaker: Philippe Aftimos, Belgium
#ESMO23: Breaking Science in Breast Cancer Video Series
Expert Report on Antibody Drug Conjugates for the Treatment of Advanced Breast Cancer
Abstracts discussed:
- 377O - A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03, presented by Sara A. Hurvitz
- 386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial, presented by Philippe G. Aftimos
- 379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study, presented by Peter Schmid
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published on 30 Oct 2023
